

# Susanne Malander

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4339293/publications.pdf>

Version: 2024-02-01

20  
papers

638  
citations

933447

10  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1342  
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1409-1419.	10.7	179
2	The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 101, 238-243.	1.4	125
3	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2018, 19, 1117-1125.	10.7	95
4	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1836-1850.	3.8	42
5	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 83-91.	2.8	41
6	Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. <i>Cell Reports</i> , 2018, 23, 2819-2831.e5.	6.4	36
7	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015, 8, 424-433.	3.7	27
8	Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2017, 7, 109.	2.8	20
9	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e107643.	2.5	17
10	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. <i>PLoS ONE</i> , 2020, 15, e0240418.	2.5	15
11	Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. <i>Scientific Reports</i> , 2019, 9, 15506.	3.3	10
12	SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1805094.	0.7	7
13	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. <i>Genes</i> , 2021, 12, 742.	2.4	6
14	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 860-868.	1.4	4
15	The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC). <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1235-1243.	1.7	4
16	Ovarian tumor frozen section, a multidisciplinary affair. <i>Acta Oncologica</i> , 2022, 61, 785-792.	1.8	4
17	Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 2541-2551.	1.1	3
18	Independent review of AGO-OVAR 12, a GCI/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study. <i>BMC Cancer</i> , 2021, 21, 465.	2.6	1
20	Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 320-325.	1.8	0